We came across a bullish thesis on Travere Therapeutics, Inc. on HalfBakedInnovations’s Substack by Biotech Distilled. In this article, we will summarize the bulls’ thesis on TVTX. Travere Therapeutics, Inc.'s share was trading at $30.07 as of February 9th. TVTX’s forward P/E was 26.32 respectively according to Yahoo Finance.
[caption id="attachment_566516" align="aligncenter" width="750"]Travere Therapeutics (TVTX) is a biotech company focused on rare kidney and metabolic diseases, with its lead asset FILSPARI (sparsentan)...
Create a free account, or log in to read the full article
No credit card required.
We may use your email to send marketing emails about our services. Click here to read our privacy policy.